Tirzepatide Efficacy and Safety Compared to Dulaglutide in Japanese Type 2 Diabetes Patients

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Current treatments often involve GLP-1 receptor agonists (GLP-1RAs) like dulaglutide, which improve glycemic control and offer cardiovascular benefits. However, there's a continuous need for therapies with enhanced efficacy and safety profiles, particularly in diverse populations. Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, represents a potential advancement, prompting direct comparisons to established GLP-1RAs to assess its relative benefits. This study specifically addresses the need for data in Japanese patients.

This Phase 4, randomized, open-label, active-controlled study compared Tirzepatide to dulaglutide in adults with Type 2 Diabetes in Japan. Participants were randomized to receive either weekly Tirzepatide or weekly dulaglutide. The primary objective was to evaluate the efficacy and safety of Tirzepatide against dulaglutide. Key endpoints included changes in HbA1c and body weight, alongside comprehensive safety and tolerability profiles. This design allowed for a direct comparison of the novel dual agonist with an established GLP-1RA.